( )2018 58 1 JournalofNanchangUniversity(MedicalSciences)2018,Vol.58No.1 55 HER2 ( 518035) : IHC HER2 FISH HER2, HER-2 2010 2015 463, FISH HER2 IHC HER2 ER PR Ki67 P53 463 HER2 35.64%(165/463),HER2 26.35% (122/463);HER2 + - HER2 91.50% 10.00% 8.27% 7.14%;HER2 (r=0.140 r= 0.310, P<0.01) (r=0.103 P<0.05,r=0.499,P<0.01) (r=0.175 r=0.220, P<0.01) Ki67 (r=0.220 r=0.331, P<0.01), ER(r=-0.406 r=-0.382, P<0.01) PR (r=-0.610 r=-0.635, P<0.01) FISH IHC, HER2 FISH ;HER2 Ki67 ER PR : ;HER2; ; : R737.9 : A : 2095-4727 (2018)01-0055-05 DOI:10.13764/j.cnki.ncdm.2018.01.013 RelationshipbetweenHER2ExpressionandClinicopathological CharacteristicsinBreastCancer YANGYa-jie,SUNYan-hua (Departmentof Pathology,Shenzhen Second People s Hospital,Shenzhen518035,China) ABSTRACT:Objective ToinvestigatetheexpressionofHER2inbreastcarcinomasbyperform- ingimmunohistochemistry(ihc)andfluorescentinsituhybridization(fish),andtoanalyzethe relationshipbetween HER2expressionandclinicopathologicalcharacteristics.Methods Theex- pressionofher2genewasdetectedbyfishandtheexpressionofher2,er,pr,ki67andp53 proteinwasmeasuredbyihcin463breastcancersamplescolectedfrom2010to2015.thecon- sistencybetween HER2geneandproteinexpressionandtherelationshipbetween HER2expres- sionandclinicopathologicalcharacteristicswereanalyzed.results HER2geneamplificationrate andproteinexpressionratewere35.64%(165/463)and26.35%(122/463),respectively.further- more,her2geneamplificationrateswere91.50%,10.00%,8.27% and7.14% inihc HER2,,+ and-samples,respectively.thegeneamplificationandproteinexpressionof HER2 werepositivelycorrelatedwithpathologicalgrade(r=0.140,r=0.310;p<0.01),tumorsize(r= 0.103,P<0.05;r=0.499,P<0.01),lymphnodemetastasis(r=0.175,r=0.220;P<0.01)and :2017-06-01 : (JCYJ20150330102720174) : (1986 ), :,E-mail:syhbeibei@126.com
56 Ki67expression(r=0.220,r=0.331;P<0.01),butnegativelycorrelatedwithER(r=-0.406, r=-0.382;p<0.01)andprexpression(r=-0.610,r=-0.635;p=0.01).conclusion The IHCandFISH haveagoodconsistencyandcorrelationfordetecting HER2expression.However, thereisalowconsistencybetween HER2proteinexpressionandgeneamplificationin HER2 cases,suggestingthattheher2shouldbefurtherdetectedbyfish.theexpressionofher2is associatedwithki67,er,pr,lymphnodemetastasis,tumorsizeandpathologicalgrade. KEY WORDS:breastcancer;HER2;immunohistochemistry;fluorescentinsituhybridization HER2 [1], 40 [2], 1.3 HER2 BRCA1 BRCA2 TP53 c-myc 10% 6~ HER2 12h ( 4μm), 7,1 HE,5 IHC,1 (FDA) 2002 HER2 Herceptin( [3] [4], ) Ki-67, p53 ER PR HER2 p53 ER PR HER2 FISH HER2, FDA (FISH),-20 (IHC) HER2 1.4 [5],HER2, [6] HER2 1)IHC:, HER2, FISH IHC Ki-67 p53 ER PR HER2,HER2 HER2 ( ) :ER PR 1 0% ~5% (-),5% ~25% 1.1 (+),25% ~50% ( ), 50% 2010 1 2015 12 ( );HER2 10% 463, 0,>10% 54 (28~80 ), +,>10% / 425 (91.79%), 20 (4.32%), 10% 3 (0.65%), 8,>10% (1.73%) 4 (0.86%) 3 (0.65%), Elston&Elis I (50 ) I (214 ) Ⅲ (161 ) 1.2 ( )2018 2, 58 1 FISH 1)IHC: MaxVision, HER2 2)FISH: HER2, 2)FISH: 30, HER2 CEP17(17 ), ER PR p53 Ki-67 HER2 2013 / (AS- / IgG CO/CAP)
: HER2 57 1.5 <2, <4( 1) SPSS19.0, HER2 35.64% (165/463) Kappa IHC FISH IHC :HER2, (%) ( 2);IHC - +, spearman P< 0.05 2 29.16%(135/463) 20.73% (96/463) 23.76%(110/463) 26.35%(122/463) IHC HER2 - + FISH (Kappa= 2.1 0.502,P<0.01) (r=0.725,p<0.01), FISH :HER2 1 ; A: ;B: HER2 1 FISH IHC A: HER2 +;B: HER2 ;C: HER2 2 IHC HER2 (MaxVision 100) 1 FISH IHC FISH - 133 0 2 135 + 80 0 16 96 73 3 34 110 7 2 113 122 293 5 165 463 ( P<0.05) 2 P53 HER2 ( P>0.05) 2 2.3 HER2 ER PR HER2 ( P< 0.01),Ki67 HER2 ( P< 2.2 HER2 0.01) 2 P53 HER2 ER PR HER2 ( P>0.05) 2 ( P<0.01),Ki67 HER2
58 ( )2018 2, 58 1 / n 2 HER2 FISH Her-2 IHC Her-2 P r - + P r 35 55 39 0 16 0.233 0.056 16 13 16 10 0.452 0.035 >35 408 254 5 149 119 83 94 112 I 50 37 0 13 <0.01 0.140 34 15 10 1 <0.01 0.310 I 214 150 1 63 63 50 49 42 I 161 77 4 80 28 22 41 70 20 17 0 3 8 6 5 1 3 2 0 1 0 0 2 1 8 6 0 2 1 1 2 4 4 2 0 2 1 2 0 1 3 2 0 1 0 0 1 2 l/cm <2 111 88 0 23 <0.05 0.103 70 23 11 7 <0.01 0.499 2~<5 224 123 5 96 52 54 76 42 5 128 82 0 46 13 19 23 73 207 150 3 54 <0.01 0.175 74 51 51 31 <0.01 0.220 256 143 2 111 61 45 59 91 ER - 115 40 3 72 <0.01-0.406 5 12 38 60 <0.01-0.382 + 96 55 0 41 28 7 41 20 124 85 1 38 28 41 13 42 128 113 1 14 74 36 18 0 PR - 95 13 4 78 <0.01-0.610 4 5 27 59 <0.01-0.635 + 88 39 1 48 8 23 28 29 152 119 0 33 36 33 51 32 128 122 0 6 87 35 4 2 P53-187 127 0 60 0.117 0.073 82 17 25 63 0.112 0.074 + 276 166 5 105 53 79 85 59 Ki67 14% 145 115 0 30 <0.01 0.220 62 40 38 5 <0.01 0.331 >14% 318 178 5 135 73 56 72 117 3 [9-10] HER2 17q12 21.32 HER2/CEP17 >2.0 HER2 < 4.0 [11] 2014,IHC, 30% 10%, [11] >10% / (ASCO/CAP) HER2,HER2 HER2 2006 2009 [7] [8] 2014 3 2014 2009 2014 HER2 22% ~30%,,HER2 11% ~44%, FISH HER2/CEPl7, 256,HER2 2.0 35.55%,HER2 43.36%;
: HER2 59 207,HER2 14.98%, HER2 26.09%, HER2 HER2 (P <0.01) HER2,IHC HER2 FISH [12] [13] 150 HER2 :, [1], 2009:426-427. HER2, HER2 463 IHC FISH, :HER2 - + 92.20%, 90% [14],HER2 122 113 FISH HER2,ASCO/ CAP HER2 IHC -, IHC FISH HER2 110 73 FISH,3 FISH, 33.64%(37/110) FISH, Hammock [15],IHC-HER2 FISH-HER2, HER2 [9],. 17, [16] FISH, FISH 15% HER2, IHC-HER2 FISH-HER2 (GPA) HER2 Hou [17] HER2,ER PR HER2,, Pathol,1996,27(9):955-963. Ki67 HER2 393-396. HER2 Panjwani [18],HER2 Ki67 ER PR 18:3471-3479.,HER2 FISH IHC. [M]. :, ture,2012,486(7403):400-404. [2] StephensPJ,TarpeyPS,Davies H,etal.Thelandscapeof cancergenesandmutationalprocessesinbreastcancer[j].na- [3] AlbanelJ,CodonyJ,RoviraA,etal.Mechanism ofactionof anti-her2monoclonalantibodies:scientificupdateontrastu- zumaband2c4[j].advexp MedBiol,2003,532:253-268. [4],. [J].,2006,28(4):241-243. [5] SwiatoniowskiG,Dabrowska M,KlaniewskiT,etal.Erb-2 overexpressioninbreastcancer[j].ginekolpol,2003,74(4): 332-338. [6] VandenBI,VanLP,Drijkoningen M,etal.Polysomy17in breastcancer:clinicopathologic significance and impact on HER2testing[J].JClinOncol,2008,26:4869-4874. [7] HER2 (2014 ). HER2 :2014 [J].,2014,43(4):262-267. [8] HER2 (2009 ). HER2 :2009 [J].,2009,38(12):836-840. 2013 / HER2 1501 HER2 [J].,2015,44(1): 42-47. [10],. 2013 ASCO/CAP HER2 549. [11]. HER2 (2014 ) [J].,2015,44(4):227-229. [12] MaleyFP,SaadZ,KerkvlietN,etal.Thepredictivepower ofsemiquantitativeimmunohistochemicalassessmentofp53 andc-erbb-2inlymphnode-negativebreastcancer[j].hum [13],,,. HER2 [J].,2016,45(6): 1780 HER2 [J].,2016,45(8):545- [14] BerryD A,MussH B,ThorA D,etal.HER2/neuandP53 expressionversustamoxifenresistanceinestrogenreceptor- positivenode-positivebreastcancer[j].jclin Oncol,2000, ( 64 )
64 VAS 12h (T 4-6 ), 0.5%,TPVB, 915-925., Dex,Dex(0.1~1μg kg -1 ) 2014,17:E589-E598. [10-11], R,DR PCA, 24~48h (T 7-9 ) VAS Dex [7],, R,DR IL-6 TNF-α 472-475. MMSE Dex [8], 143. Dex :α2 G [12],Dex 1191. P [13], [11], Dex [12] Dex : sches rzteblatinternational,2014,111(8):119. [2]. [J].,2013,29(1):31-34. [1] RundshagenI.Postoperativecognitivedysfunction[J].Deut- [3] Chen W,LiuB,ZhangF,etal.Theefectsofdexmedetomidine onpost-operativecognitivedysfunctionandinflammatoryfac- torsinsenilepatients[j].intjcliniexperimentalmed,2015, 8(3). [4] AbdalahF W,BrulR.Facilitatoryefectsofperineuraldexme- detomidineonneuraxialandperipheralnerveblock:asystematic reviewandmeta-analysis[j].britj Anaesth,2013,110(6): [5] MohamedSA,FaresK M,MohamedA A,etal.Dexmedetomi- dineasanadjunctiveanalgesicwithbupivacaineinparaverte- bralanalgesiaforbreastcancersurgery[j].pain Physician, ativecognitivedysfunction:involvementofneuroinflammation andneuronalfunctioning[j].brain BehavImmun,2014,38: 202-210.,. [J].,2016,32(5): [6] HovensIB,SchoemakerR G,vanderZeeE A,etal.Postoper-,. [J].,2016,36(2):140- [9] Pace M M,SharmaB,AndersonDamJ,etal.Ultrasound-guided thoracicparavertebralblockade:aretrospectivestudyoftheinci- denceofcomplications[j].anesthanalg,2016,122(4):1186- vacaine[j].janaesthesiolclinpharmacol,2011,27(3):339.. [J].,2015,2:008.,. [J].,2016,32(12):1165-1168. [13] YoshitomiT,KohjitaniA,MaedaS,etal.Dexmedetomidine enhancesthelocalanestheticactionoflidocaineviaanα-2a adrenoceptor[j].anesthanalg,2008,107(1):96-101. ( : ) 櫐櫐櫐櫐櫐櫐櫐櫐櫐櫐櫐櫐櫐櫐櫐櫐櫐櫐櫐櫐櫐櫐櫐櫐櫐櫐櫐櫐櫐櫐櫐櫐櫐櫐櫐櫐櫐櫐櫐櫐櫐櫐櫐櫐櫐櫐櫐櫐櫐 ( 59 ) [10] GuptaR,VermaR,BograJ,etal.A Comparativestudyofin- trathecaldexmedetomidineandfentanylasadjuvantstobupi- [15] HammockL,Lewis M,PhilipsC,eta1.Strong HER2/neu proteinoverexpressionbyimmunohistochemistryoftendoes notpredictoncogeneamplificationbyfluorescenceinsituhy- bridization[j].hum Pathol,2003,34(10):1043-1047. ogistsclinicalpracticeguidelineupdate[j].j Clin Oncol, 2013,31(31):3997-4013. [17] HouY,NitaH,LiZ.HER2geneproteinassayisusefulto determineher2statusandevaluateher2heterogeneityin HER2equivocalbreastcancer[J].Am JClinPathol,2017, 147(1):89-95. [18] PanjwaniP,EpariS,KarpateA,etal.AssessmentofHER2/ [16] PerezE A,Clinic M E.Recommendationsforhumanepider- malgrowthfactorreceptor2testinginbreastcancer:ameri- cansocietyofclinicaloncology/colegeofamericanpathol- neustatusinbreastcancerusingfluorescenceinsituhybrid- ization &immunohistochemistry:experience of a tertiary cancerreferralcentreinindia[j].indianj Med Res,2010, 132:287-294. ( )2018 2, 58 1 ( : )